This study examines treatments for high-risk head and neck cancer that starts in thin, flat cells called squamous cells. It compares the usual treatment of radiation and chemotherapy (cisplatin) with new combinations including docetaxel, cetuximab, and immunotherapy drug atezolizumab. Cisplatin and docetaxel are chemotherapy drugs that kill cancer cells. Cetuximab is a monoclonal antibody that may stop cancer cells from growing. Atezolizumab is an immunotherapy that helps the immune system attack cancer.

Key Points:

• The study involves different treatment combinations and lasts for about 6 weeks.
• Participants need to visit the clinic for treatments and follow-ups, including radiation and drug infusions.
• Potential side effects include typical chemotherapy side effects like nausea and fatigue.

Participants will be monitored through blood tests, CT, and MRI scans. This study aims to find the best treatment option with the fewest side effects. Patients should discuss with their doctor if they meet eligibility criteria and consider the risks and benefits of participating. Follow-ups continue for several years to monitor long-term effects.